Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison. (Record no. 29012310)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01173 a2200277 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518005103.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201905s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1096-1186 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/j.phrs.2018.11.003 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Motaghi, Ehsan |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20190513 |
| 245 00 - TITLE STATEMENT | |
| Title | Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Pharmacological research |
| Date of publication, distribution, etc. | 01 2019 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 120-125 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Colitis, Ulcerative |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gastrointestinal Agents |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Infliximab |
| General subdivision | therapeutic use |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ghasemi-Pirbaluti, Masoumeh |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zabihi, Mohsen |
| 773 0# - HOST ITEM ENTRY | |
| Title | Pharmacological research |
| Related parts | vol. 139 |
| -- | p. 120-125 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/j.phrs.2018.11.003">https://doi.org/10.1016/j.phrs.2018.11.003</a> |
| Public note | Available from publisher's website |
No items available.